REVB (Revelation Biosciences) Total Assets: $15.04 Mil (As of Mar. 2026)


REVB Revelation Biosciences Inc REVB
28 GF Score
Price $0.98
! 1 Warning Sign
View Full Analysis

What is Revelation Biosciences Total Assets?

Revelation Biosciences REVB +3.16% 28 Total Assets is $15.04 Mil as of Mar. 2026. GuruFocus rates REVB with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

Revelation Biosciences's Total Assets for the quarter that ended in Mar. 2026 was $15.04 Mil.

During the past 12 months, Revelation Biosciences's average Total Assets Growth Rate was 617.90% per year. During the past 3 years, the average Total Assets Growth Rate was 52.30% per year. During the past 5 years, the average Total Assets Growth Rate was 12.20% per year.

During the past 6 years, Revelation Biosciences's highest 3-Year average Total Assets Growth Rate was 52.30%. The lowest was -45.70%. And the median was 20.00%.

Total Assets is connected with ROA %. Revelation Biosciences's annualized ROA % for the quarter that ended in Mar. 2026 was -90.40%. Total Assets is also linked to Revenue through Asset Turnover. Revelation Biosciences's Asset Turnover for the quarter that ended in Mar. 2026 was 0.00.

Revelation Biosciences  (NAS:REVB) Total Assets Explanation

Total Assets is connected with ROA %.

Revelation Biosciences's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-12.036/( (11.583+15.044)/ 2 )
=-12.036/13.3135
=-90.40 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Revelation Biosciences's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=0/( (11.583+15.044)/ 2 )
=0/13.3135
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Revelation Biosciences Total Assets Related Terms

Revelation Biosciences Total Assets Historical Data

* Premium members only.

The historical data trend for Revelation Biosciences's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Revelation Biosciences Total Assets Chart

Revelation Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial 2.04 5.50 12.21 6.62 11.58

Revelation Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.97 5.40 12.86 11.58 15.04
REVB
28GF Score
Revelation Biosciences Inc REVB
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Revelation Biosciences Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Revelation Biosciences's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=8.861+2.722
=11.58

Revelation Biosciences's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=12.989+2.055
=15.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $15.04 Mil mean?
Revelation Biosciences (REVB) has a Total Assets of $15.04 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Revelation Biosciences and its competitors.
Is Revelation Biosciences' Total Assets too high?
Revelation Biosciences' current Total Assets is $15.04 Mil. Overall, Revelation Biosciences has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Revelation Biosciences' Total Assets compare to ITRMF and ENSC?
Revelation Biosciences' Total Assets of $15.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Revelation Biosciences and its competitors. Revelation Biosciences's current Total Assets is $15.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revelation Biosciences stock overvalued right now?
Revelation Biosciences (REVB) has a current Total Assets of $15.04 Mil. The current Total Assets is $15.04 Mil. Revelation Biosciences' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Revelation Biosciences (REVB), the current Total Assets is $15.04 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Revelation Biosciences Business Description

Address 4660 La Jolla Village Drive, Suite 100, San Diego, CA, USA, 92122
Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.
28GF Score

Get the complete analysis for REVB

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.98
Price